Brenda F Kurland

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. doi request reprint Accommodation of missing data in supportive and palliative care clinical trials
    Brenda F Kurland
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98019, USA
    Curr Opin Support Palliat Care 6:465-70. 2012
  2. pmc Promise and pitfalls of quantitative imaging in oncology clinical trials
    Brenda F Kurland
    Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
    Magn Reson Imaging 30:1301-12. 2012
  3. pmc Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
    EJNMMI Res 2:34. 2012
  4. ncbi request reprint Longitudinal change in positive affect in community-dwelling older persons
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Am Geriatr Soc 54:1846-53. 2006
  5. pmc Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET
    Brenda F Kurland
    Department of Clinical Statistics, Fred Hutchinson Cancer Research Center, Seattle Washington 98109, USA
    J Nucl Med 52:1541-9. 2011
  6. pmc PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake
    Lisa K Dunnwald
    Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:2400-9. 2011
  7. pmc Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98109 1023, USA
    J Magn Reson Imaging 32:1124-31. 2010
  8. pmc Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
  9. doi request reprint Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value
    Savannah C Partridge
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    AJR Am J Roentgenol 193:1716-22. 2009
  10. doi request reprint Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    AJR Am J Roentgenol 194:1664-73. 2010

Detail Information

Publications34

  1. doi request reprint Accommodation of missing data in supportive and palliative care clinical trials
    Brenda F Kurland
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98019, USA
    Curr Opin Support Palliat Care 6:465-70. 2012
    ..Clinical trials to evaluate the supportive and palliative care treatments have some different missing data concerns than the other clinical trials. This study reviews the literature on missing data as it may apply to these trials...
  2. pmc Promise and pitfalls of quantitative imaging in oncology clinical trials
    Brenda F Kurland
    Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
    Magn Reson Imaging 30:1301-12. 2012
    ..Strategies for overcoming these constraints are presented...
  3. pmc Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
    EJNMMI Res 2:34. 2012
    ..abstract:..
  4. ncbi request reprint Longitudinal change in positive affect in community-dwelling older persons
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Am Geriatr Soc 54:1846-53. 2006
    ..To determine whether positive affect, defined as emotional contentment and happiness, remains stable in late life and to identify predictors of longitudinal change in positive affect...
  5. pmc Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET
    Brenda F Kurland
    Department of Clinical Statistics, Fred Hutchinson Cancer Research Center, Seattle Washington 98109, USA
    J Nucl Med 52:1541-9. 2011
    ..We describe within-patient (site-to-site) and between-patient heterogeneity of lesions in patients scheduled to receive endocrine therapy...
  6. pmc PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake
    Lisa K Dunnwald
    Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:2400-9. 2011
    ..Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS)...
  7. pmc Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98109 1023, USA
    J Magn Reson Imaging 32:1124-31. 2010
    ....
  8. pmc Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
    ..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
  9. doi request reprint Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value
    Savannah C Partridge
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    AJR Am J Roentgenol 193:1716-22. 2009
    ..The purpose of our study was to investigate whether adding diffusion-weighted imaging (DWI) to dynamic contrast-enhanced MRI (DCE-MRI) could improve the positive predictive value (PPV) of breast MRI...
  10. doi request reprint Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    AJR Am J Roentgenol 194:1664-73. 2010
    ..The purpose of this study was to determine whether lesion type and size affect discrimination of benign and malignant breast lesions with diffusion-weighted MRI...
  11. pmc Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer
    Hannah M Linden
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 17:4799-805. 2011
    ..To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy...
  12. pmc Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer
    Jennifer M Specht
    Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 16:2803-10. 2010
    ..This analysis examines tumor metabolism and perfusion by tumor subtype...
  13. ncbi request reprint Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
    ..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
  14. pmc Quantitative assessment of dynamic PET imaging data in cancer imaging
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Magn Reson Imaging 30:1203-15. 2012
    ....
  15. pmc Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer
    Peter R Eby
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, G3 200, Seattle, WA 98109 1023, USA
    Acad Radiol 15:1246-54. 2008
    ....
  16. doi request reprint Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristics
    Wendy B Demartini
    Department of Radiology, University of Washington Medical Center, 1959 NE Pacific, Seattle, WA 98195, USA
    Eur Radiol 21:1609-17. 2011
    ..To predict the probability of malignancy for MRI-detected breast lesions with a multivariate model incorporating patient and lesion characteristics...
  17. doi request reprint Preoperative and intraoperative sonographic visibility of collagen-based breast biopsy marker clips
    Peter R Eby
    Department of Radiology, University of Washington Medical Center, Seattle, WA, USA
    Acad Radiol 17:340-7. 2010
    ..The aim of this study was to determine the sonographic visibility of implanted collagen-based breast biopsy marker clips in the clinic and operating room...
  18. pmc Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF
    Robert K Doot
    Department of Bioengineering, University of Washington, Seattle, Washington, USA
    J Nucl Med 48:920-5. 2007
    ..We tested whether chemotherapy and treatment with granulocyte colony-stimulating factor (CSF) changed the blood clearance curves and therefore affected the relationship between MRFDG and SUV...
  19. doi request reprint Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer
    Lanell M Peterson
    Department of Radiology, University of Washington Medical Center, Seattle, WA 98195, USA
    Nucl Med Biol 38:969-78. 2011
    ..Assessment of factors that could affect the quantitative level of FES uptake is important as part of the validation of FES PET for evaluating regional ER expression in breast cancer...
  20. pmc Design considerations for using PET as a response measure in single site and multicenter clinical trials
    Robert K Doot
    Department of Radiology, University of Washington, Seattle, 98109 1023, USA
    Acad Radiol 19:184-90. 2012
    ..Here we demonstrate impacts of PET measurement error and choice of quantification method on clinical trial design...
  21. doi request reprint BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement
    Robert L Gutierrez
    Department of Radiology, University of Washington Medical Center, University of Washington, Seattle, WA
    AJR Am J Roentgenol 193:994-1000. 2009
    ..The purpose of our study was to evaluate the predictive features of BI-RADS lesion characteristics and the risk of malignancy for mammographically and clinically occult lesions detected initially on breast MRI...
  22. doi request reprint Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI
    Savannah C Partridge
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109 1023, USA
    J Magn Reson Imaging 31:562-70. 2010
    ..To investigate the diagnostic performance of diffusion-weighted imaging (DWI) for mammographically and clinically occult breast lesions...
  23. ncbi request reprint Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer
    Michelle S Yao
    Department of Radiation Oncology, University of Washington Medical School, Seattle, WA, USA
    Ann Surg Oncol 14:2985-93. 2007
    ..Internal mammary (IM) nodes are a potential site of breast lymphatic drainage. We examined the relationship between lymphoscintigraphic evidence of IM drainage and survival in early-stage breast cancer patients (pts)...
  24. doi request reprint Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs
    Brenda F Kurland
    aFred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Trials 10:886-95. 2013
    ..However, it is often unknown how measurement error and bias in a multicenter trial will differ from that in single-institution studies...
  25. doi request reprint Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial
    Renato G Martins
    University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave E MS G4 940, Seattle, WA 98109, USA
    J Clin Oncol 31:1415-21. 2013
    ..Erlotinib is a small-molecule inhibitor of EGFR. Adding EGFR inhibition to standard cisplatin-radiotherapy may improve efficacy...
  26. doi request reprint Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes
    Julie E Bauman
    Department of Medical Oncology, University of Washington, Seattle, Washington, USA
    Ann Thorac Surg 86:1632-8; discussion 1638-9. 2008
    ..Although originally considered inoperable, select patients are referred for surgical salvage. We describe a series of salvage lung resection after curative-intent radiation...
  27. ncbi request reprint Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths
    Brenda F Kurland
    National Alzheimer s Coordinating Center, University of Washington, 4311 11th Avenue NE 300, Seattle, WA 98105, USA
    Biostatistics 6:241-58. 2005
    ..Simulation studies and an analysis of monthly disability status illustrate potential bias in regression methods that do not explicitly condition on survival...
  28. pmc Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years
    Karen L Syrjala
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    J Clin Oncol 29:2397-404. 2011
    ..This study prospectively examined the trajectory and extent of long-term cognitive dysfunction, with a focus on 1 to 5 years after treatment...
  29. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012
    ..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
  30. doi request reprint Clinical indication and patient age predict likelihood of malignancy in suspicious breast MRI lesions
    Robert L Gutierrez
    Department of Radiology, University of Washington Medical Center, University of Washington, Seattle, WA, USA
    Acad Radiol 16:1281-5. 2009
    ..To evaluate the associations of patient age and clinical indication with the risk of malignancy for suspicious lesions initially detected on breast magnetic resonance imaging (MRI)...
  31. pmc Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years
    Karen L Syrjala
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 111:989-96. 2008
    ..05) reported problems. Thus, despite some recovery, sexual dysfunction remained a major problem for men and women after HCT. Aggressive efforts are needed to treat these deficits...
  32. ncbi request reprint Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out
    Brenda F Kurland
    National Alzheimer s Coordinating Center, University of Washington, Department of Epidemiology, 4311 11th Ave NE 300, Seattle, WA 98105, USA
    Stat Med 23:2673-95. 2004
    ..MTM and IPCW-GEE regression parameters both display misspecification bias for MAR and non-ignorable missing data, and both reduce bias noticeably by improving model fit...
  33. ncbi request reprint Prognostic effect of prior disability episodes among nondisabled community-living older persons
    Thomas M Gill
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06504, USA
    Am J Epidemiol 158:1090-6. 2003
    ..More frequent assessments of functional status may be warranted in epidemiologic studies and clinical trials when disability is a primary focus...
  34. ncbi request reprint A 3-dimensional analysis of molar movement during headgear treatment
    Jennifer L Ashmore
    Department of Orthodontics, University of Washington, Seattle 98195 7446, USA
    Am J Orthod Dentofacial Orthop 121:18-29; discussion 29-30. 2002
    ..Several reasons could account for the wide range of individual variation and warrant exploration...